Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.76 -0.32 (-0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
41 42 Next >
News headline image
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market ↗
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. 
Via The Motley Fool
News headline image
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? ↗
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
News headline image
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
News headline image
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
News headline image
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock? ↗
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
News headline image
Is Sanofi Stock a Buy Now? ↗
The pharma giant has outperformed the broader market over the past 12 months. 
Via The Motley Fool
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Why Shares of Regeneron Are Rising Thursday ↗
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
News headline image
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review ↗
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration ↗
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
News headline image
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data ↗
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
News headline image
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' ↗
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
News headline image
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study ↗
 
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today ↗
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
News headline image
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
News headline image
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78% ↗
 
Via Benzinga
News headline image
Why Provention Bio Stock Skyrocketed 256% This Week ↗
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. 
Via The Motley Fool
News headline image
What's Going On With Sanofi Stock After Hours? ↗
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States  
Via Benzinga
News headline image
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.